Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Terazosine Clear all
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 6, 2026, 2:24 PM EDT
Recruiting Early Phase 1 Interventional

Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

NCT07224269
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities
Interventions
Terazosine, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 2:24 PM EDT
Active, not recruiting Phase 2 Interventional

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

NCT04386317
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease
Interventions
Terazosin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 6, 2026, 2:24 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Terazosin for Dementia With Lewy Bodies

NCT04760860
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Terazosin Hydrochloride, Placebo
Drug · Other
Lead sponsor
Qiang Zhang
Other
Eligibility
0 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 6, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of Terazosin for Parkinson's Disease

NCT03905811
View directory record Official record
Conditions
Parkinson Disease
Interventions
Terazosin 5 MG, Placebo oral capsule
Drug
Lead sponsor
Jordan Schultz
Other
Eligibility
40 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 6, 2026, 2:24 PM EDT
Active, not recruiting Phase 2 Interventional

Terazosin and Parkinson's Disease Extension Study

NCT05109364
View directory record Official record
Conditions
Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Interventions
Terazosin therapy
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 6, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

NCT00237510
View directory record Official record
Conditions
Antidepressant Induced Excessive Sweating
Interventions
terazosin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 6, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

NCT00449683
View directory record Official record
Conditions
Hyperhidrosis
Interventions
terazosin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 6, 2026, 2:24 PM EDT
Not yet recruiting Phase 2 Interventional

Terazosin And Metabolic Engagement in Alzheimer's Disease

NCT07796308
View directory record Official record
Conditions
Alzheimer s Disease
Interventions
Terazosin (Hytrin), Placebo
Drug · Other
Lead sponsor
Qiang Zhang
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 6, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

NCT02046395
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
amlodipine, hydralazine, terazosin or hydrochlorothiazide
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 6, 2026, 2:24 PM EDT
Not listed Phase 2 Interventional

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

NCT03339258
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Doxazosin Mesylate, Extended Release, Placebo
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 6, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 6, 2026, 2:24 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Target Engagement of Terazosin in Healthy Adults

NCT04551040
View directory record Official record
Conditions
Healthy
Interventions
Terazosin
Drug
Lead sponsor
University of Iowa
Other
Eligibility
60 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 6, 2026, 2:24 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Diesel Exhaust and Vascular Function

NCT01508637
View directory record Official record
Conditions
Cardiovascular Effects
Interventions
Diesel Exhaust, Filtered Air, Terazosin, placebo
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 6, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

NCT01366664
View directory record Official record
Conditions
Ejaculation
Interventions
Treatment sequence 2, Treatment sequence 1
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Anniston, Alabama • Tempe, Arizona • Costa Mesa, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 6, 2026, 2:24 PM EDT